{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"88"}],"units":"Participants"}],"description":"Number of participants with neurotoxicity observed treated with l-glutamic acid hydrochloride as compared to the number of participants with neurotoxicity observed in the placebo control group","groups":[{"description":"Patients receive oral glutamic acid 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).\n\nglutamic acid: Given orally 3 times daily","id":"OG000","title":"Arm I Glutamic Acid"},{"description":"Patients receive oral placebo 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).\n\nplacebo: Given orally 3 times daily","id":"OG001","title":"Arm II Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Stratum 2 with a \\>= grade 2 neurotoxicity","reportingStatus":"POSTED","timeFrame":"10 weeks","title":"Number of Participants With Neurotoxicity Observed","type":"SECONDARY","unitOfMeasure":"Participants"}